File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Impact of a multimodality treatment strategy on the survival outcomes in patients with recurrent hepatocellular carcinoma

TitleImpact of a multimodality treatment strategy on the survival outcomes in patients with recurrent hepatocellular carcinoma
Authors
Issue Date2013
PublisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
Citation
Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL Liver Week 2013), Singapore, 6-9 June 2013. In Hepatology international, 2013, v. 7 n. 1 suppl., p. S638, abstract no. 2848 How to Cite?
AbstractINTRODUCTION: The prognosis of patients with tumor recurrence after hepatectomy was dismal. However, it is uncertain if recent advances in the surgical management of hepatocellular carcinoma (HCC) could also improve the survival outcomes of this condition. OBJECTIVE: To evaluate the prognostic impact of a multimodality treatment strategy for intrahepatic recurrence after hepatectomy. MATERIALS AND METHODS: Data was reviewed for 469 patients with post-hepatectomy intrahepatic recurrence who received secondary treatments from 1993 to 2008. Transarterial chemoembolization (n=128) was the mainstay of treatment during 1993-2000 i.e Era I, n=170 while re-resection(RR), radiofrequency ablation (RFA) and salvage transplantation were adopted during 2001-2008 i.e. Era II, n=299. Survival outcomes of the two eras were analyzed. RESULTS: Patients in Era II were at more advanced age (P=0.03) and had higher incidence of comorbid illness (P=0.008). There was no significant difference in liver function and tumor characteristics between the two eras. However, there was a significant increment in the number of patients receiving secondary surgical treatments from 12.9% in Era I to 36.1% in Era II (P< 0.001), with a reciprocal reduction in the number of transarterial chemoembolizations (Era I 75.3% to Era II 49.2%, P< 0.001). The most notable increment was the number of RR (Era I: 4.7% vs. Era II 14.7%) and RFA (Era I: 0% vs. Era II 21.7%). As a result, the overall median survival was improved from 41.4 months in Era I to 56.5 months in Era II (P=0.002). The 1-, 3- and 5-year overall survival rates in Era I were 81.1%, 55.6% and 36.7% and for Era II were 87.6%, 62.6% and 46.6%, respectively. CONCLUSION: Recent advances in the surgical management of HCC have also enhanced the chance for treatments of intrahepatic recurrence. A multimodality treatment strategy is imperative to improve the prognosis of patients with post-hepatectomy tumor recurrence.
DescriptionConference Theme: Transforming Science to Clinical Practice
Topic: 13.b Clinical
This journal suppl. entitled: Abstracts - APASL 2013
Persistent Identifierhttp://hdl.handle.net/10722/185082
ISSN
2015 Impact Factor: 1.125
2015 SCImago Journal Rankings: 0.669

 

DC FieldValueLanguage
dc.contributor.authorChan, A-
dc.contributor.authorPoon, R-
dc.contributor.authorCheung, TT-
dc.contributor.authorChok, KSH-
dc.contributor.authorLo, CM-
dc.date.accessioned2013-07-15T10:29:16Z-
dc.date.available2013-07-15T10:29:16Z-
dc.date.issued2013-
dc.identifier.citationAnnual Meeting of the Asian Pacific Association for the Study of the Liver (APASL Liver Week 2013), Singapore, 6-9 June 2013. In Hepatology international, 2013, v. 7 n. 1 suppl., p. S638, abstract no. 2848-
dc.identifier.issn1936-0533-
dc.identifier.urihttp://hdl.handle.net/10722/185082-
dc.descriptionConference Theme: Transforming Science to Clinical Practice-
dc.descriptionTopic: 13.b Clinical-
dc.descriptionThis journal suppl. entitled: Abstracts - APASL 2013-
dc.description.abstractINTRODUCTION: The prognosis of patients with tumor recurrence after hepatectomy was dismal. However, it is uncertain if recent advances in the surgical management of hepatocellular carcinoma (HCC) could also improve the survival outcomes of this condition. OBJECTIVE: To evaluate the prognostic impact of a multimodality treatment strategy for intrahepatic recurrence after hepatectomy. MATERIALS AND METHODS: Data was reviewed for 469 patients with post-hepatectomy intrahepatic recurrence who received secondary treatments from 1993 to 2008. Transarterial chemoembolization (n=128) was the mainstay of treatment during 1993-2000 i.e Era I, n=170 while re-resection(RR), radiofrequency ablation (RFA) and salvage transplantation were adopted during 2001-2008 i.e. Era II, n=299. Survival outcomes of the two eras were analyzed. RESULTS: Patients in Era II were at more advanced age (P=0.03) and had higher incidence of comorbid illness (P=0.008). There was no significant difference in liver function and tumor characteristics between the two eras. However, there was a significant increment in the number of patients receiving secondary surgical treatments from 12.9% in Era I to 36.1% in Era II (P< 0.001), with a reciprocal reduction in the number of transarterial chemoembolizations (Era I 75.3% to Era II 49.2%, P< 0.001). The most notable increment was the number of RR (Era I: 4.7% vs. Era II 14.7%) and RFA (Era I: 0% vs. Era II 21.7%). As a result, the overall median survival was improved from 41.4 months in Era I to 56.5 months in Era II (P=0.002). The 1-, 3- and 5-year overall survival rates in Era I were 81.1%, 55.6% and 36.7% and for Era II were 87.6%, 62.6% and 46.6%, respectively. CONCLUSION: Recent advances in the surgical management of HCC have also enhanced the chance for treatments of intrahepatic recurrence. A multimodality treatment strategy is imperative to improve the prognosis of patients with post-hepatectomy tumor recurrence.-
dc.languageeng-
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0-
dc.relation.ispartofHepatology International-
dc.rightsThe final publication is available at Springer via http://dx.doi.org/10.1007/s12072-013-9429-0-
dc.titleImpact of a multimodality treatment strategy on the survival outcomes in patients with recurrent hepatocellular carcinoma-
dc.typeConference_Paper-
dc.identifier.emailChan, A: acchan@hku.hk-
dc.identifier.emailPoon, R: poontp@hku.hk-
dc.identifier.emailCheung, TT: cheung68@hku.hk-
dc.identifier.emailChok, KSH: chok6275@hku.hk-
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hk-
dc.identifier.authorityChan, A=rp00310-
dc.identifier.authorityPoon, R=rp00446-
dc.identifier.authorityCheung, TT=rp02129-
dc.identifier.authorityChok, KSH=rp02110-
dc.identifier.authorityLo, CM=rp00412-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s12072-013-9429-0-
dc.identifier.pmid26202133-
dc.identifier.hkuros216079-
dc.identifier.hkuros229876-
dc.identifier.volume7-
dc.identifier.issue1 suppl.-
dc.identifier.spageS638, abstract no. 2848-
dc.identifier.epageS638, abstract no. 2848-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats